🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Berlin
Clinical trial register · Germany

Clinical Trials in Berlin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 40 Munich 26 Dresden 22 Essen 21 Tübingen 20
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca115 Charite University, Berlin, Germany93 Janssen Research & Development, LLC49 Eli Lilly and Company45 Novartis Pharmaceuticals45 Clear sponsor filter
Site location
Berlin40 Munich26 Dresden22 Essen21 Tübingen20
All 98 locations
Target enrolment
to

Trials with a site in Berlin

40 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)
NCT07614984Lipoprotein(a)
DrugEnlicitide
Merck Sharp & Dohme LLC
Phase 2
750
Konstanz, Kassel, Offenbach, Stuhr, Berlin
2026-06-30
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295Bladder Cancer
DrugsVinflunine·Sacituzumab tirumotecan·Docetaxel·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
590
Berlin
2026-04-23
Recruiting
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
NCT07486960Psoriatic Arthritis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
140
Cottbus, Herne, Berlin, Hamburg
2026-04-20
Recruiting
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
NCT07489495Carcinoma, Renal Cell
DrugsZanzalintinib·Belzutifan
Merck Sharp & Dohme LLC
Phase 3
758
Augsburg, Munich, Jena, Berlin
2026-04-09
Recruiting
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
NCT07209111Neoplasm Malignant
DrugsCalderasib·Cetuximab
Merck Sharp & Dohme LLC
Phase 2
150
Leipzig, Jena, Berlin
2025-12-04
Active, closed
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
NCT07176390Arthritis, Rheumatoid
DrugsTulisokibart·Methotrexate
Merck Sharp & Dohme LLC
Phase 2
185
München, Cottbus, Ratingen, Berlin, Hamburg
2025-10-08
Recruiting
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
NCT07133633Radiographic Axial Spondyloarthritis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
315
Munich, Cottbus, Herne, Ratingen, Berlin, Hamburg
2025-09-26
Recruiting
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma
DrugsBevacizumab biosimilar·Calderasib·Cetuximab·Adrucil
Merck Sharp & Dohme LLC
Phase 3
477
Essen, Berlin, Hamburg
2025-07-16
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsXeloda·Epirubicin·Adriamycin·Paraplatin
Merck Sharp & Dohme LLC
Phase 3
2,400
Erlangen, Munich, Paderborn, Koblenz, Saarbrücken, Berlin
2025-06-30
Active, closed
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
NCT06956235Hidradenitis Suppurativa
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 2
149
Frankfurt am Main, Berlin
2025-06-09
Recruiting
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
NCT06780098Lung Neoplasm
DrugsR-DXd·Ifinatamab Deruxtecan·Taxotere·Docetaxel
Merck Sharp & Dohme LLC
Phase 2
144
Tübingen, Berlin
2025-05-28
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504Endometrial Cancer
DrugsSacituzumab tirumotecan·Docetaxel·Paclitaxel·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
1,123
Aachen, Trier, Saarbrücken, Leipzig, Jena, Berlin, Hamburg
2025-05-22
Recruiting
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
NCT06780085Carcinoma, Non-Small-Cell Lung
DrugsR-DXd·Ifinatamab Deruxtecan
Merck Sharp & Dohme LLC
Phase 2
96
Tübingen, Berlin
2025-05-13
Active, closed
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
NCT06814145Hypertension, Pulmonary
DrugSotatercept
Merck Sharp & Dohme LLC
Phase 2
440
Heidelberg, München, Giessen, Cologne, Mainz, Dresden, Berlin
2025-04-16
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354Triple Negative Breast Neoplasms
DrugsSacituzumab tirumotecan·Nab-paclitaxel·Gemcitabine·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
1,000
Erlangen, Düsseldorf, Essen, Saarbrücken, Leipzig, Berlin
2025-03-16
Recruiting
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
NCT06667700Coronavirus Disease (COVID-19)
DrugMolnupiravir
Merck Sharp & Dohme LLC
Phase 3
3,082
Munich, Frankfurt am Main, Cologne, Berlin
2024-12-02
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
DrugZilovertamab vedotin
Merck Sharp & Dohme LLC
Phase 1/2
90
Tübingen, Cologne, Münster, Berlin
2024-08-16
Active, closed
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
NCT06492291Hypercholesterolemia
DrugsEnlicitide Decanoate·Enlicitide
Merck Sharp & Dohme LLC
Phase 3
3,000
Essen, Dresden, Hohenmölsen, Bad Berka, Berlin
2024-08-05
Active, closed
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
NCT06456346Essential Thrombocythemia
DrugsBomedemstat·Hydroxyurea
Merck Sharp & Dohme LLC
Phase 3
300
Landshut, Hanover, Aachen, Essen, Mainz, Halle, Jena, Berlin
2024-07-16
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
DrugsSacituzumab tirumotecan·Nab-paclitaxel·Keytruda·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
851
Dortmund, Essen, Lübeck, Gera, Berlin
2024-06-10
Recruiting
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
NCT06353386Prostatic Neoplasms, Castration-Resistant
DrugsFludrocortisone acetate·Opevesostat·Cabazitaxel·Olaparib
Merck Sharp & Dohme LLC
Phase 1/2
220
Heidelberg, Tübingen, Munich, Berlin, Hamburg
2024-05-20
Active, closed
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
NCT06356311Gastroesophageal Cancer
DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
450
Heidelberg, Göttingen, Dresden, Kiel, Berlin, Hamburg
2024-05-03
Active, closed
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
NCT06307431Renal Cell Carcinoma
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2
272
Stuttgart, Munich, Dresden, Jena, Berlin, Hamburg
2024-04-10
Active, closed
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
NCT06305767Bladder Cancer
DrugsIntismeran autogene·Enfortumab Vedotin·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1/2
230
Munich, Regensburg, Dresden, Halle, Berlin
2024-03-28
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624Prostate Cancer Metastatic
DrugsFludrocortisone acetate·Opevesostat·Zytiga·Hydrocortisone
Merck Sharp & Dohme LLC
Phase 3
1,310
Munich, Schwerin, Bonn, Münster, Lübeck, Jena, Berlin, Hamburg
2023-12-31
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsNemtabrutinib·Ibrutinib·Acalabrutinib
Merck Sharp & Dohme LLC
Phase 3
1,200
Ulm, Landshut, Mönchengladbach, Koblenz, Halle, Berlin
2023-12-13
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
DrugsAdriamycin·Abraxane·Taxol·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
710
Heilbronn, Mannheim, Ravensburg, Tübingen, Munich, Essen, Dresden, Berlin
2023-12-06
Recruiting
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
NCT05714085Heart Failure, Left Ventricular Systolic Dysfunction
DrugVericiguat
Merck Sharp & Dohme LLC
Phase 2/3
342
Freiburg im Breisgau, Heidelberg, Erlangen, Hanover, Berlin
2023-05-31
Recruiting
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
NCT05319730Esophageal Squamous Cell Carcinoma
DrugsMK-4830·Steroid mouthwash (dexamethasone·Acetaminophen·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 1/2
230
Erdgeschoss, Frankfurt am Main, Düsseldorf, Berlin
2023-05-16
Active, closed
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
NCT05609968Carcinoma, Non-Small-Cell Lung
DrugsSacituzumab Govitecan·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
614
Mannheim, Kempten (Allgäu), Würzburg, Koblenz, Halle, Berlin
2023-02-06
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987Endometrial Neoplasms
DrugsTaxotere·Paraplatin·Taxol·Keytruda
Merck Sharp & Dohme LLC
Phase 3
280
Ulm, Bonn, Dresden, Berlin
2022-02-03
Active, closed
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms
DrugsDocetaxel·Paclitaxel·Bevacizumab·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
643
Erlangen, Bonn, Düsseldorf, Krefeld, Saarbrücken, Dresden, Leipzig, Berlin
2021-12-13
Recruiting
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
NCT04924075Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
DrugBelzutifan
Merck Sharp & Dohme LLC
Phase 2
355
Freiburg im Breisgau, München, Würzburg, Düsseldorf, Berlin
2021-08-12
Active, closed
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).
NCT04895722Colorectal Cancer
DrugsPembrolizumab/Vibostolimab·MK-4830·Pembrolizumab/Favezelimab·Pembrolizumab/Quavonlimab
Merck Sharp & Dohme LLC
Phase 2
302
Munich, Marburg, Essen, Dresden, Magdeburg, Berlin, Hamburg
2021-06-25
Active, closed
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
NCT04895358Breast Neoplasms
DrugsLiposomal doxorubicin·Xeloda·Abraxane·Taxol
Merck Sharp & Dohme LLC
Phase 3
342
Erlangen, Bonn, Düsseldorf, Essen, Dresden, Berlin
2021-06-18
Active, closed
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
NCT04736706Carcinoma, Renal Cell
DrugsPembrolizumab/Quavonlimab·Belzutifan·Lenvatinib·Keytruda
Merck Sharp & Dohme LLC
Phase 3
1,854
Tübingen, Schwerin, Berlin
2021-04-14
Active, closed
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
NCT04380636Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
DrugsParaplatin·Taxol·Olaparib·Etoposide
Merck Sharp & Dohme LLC
Phase 3
870
Göttingen, Minden, Münster, Neuss, Großhansdorf, Bad Berka, Jena, Berlin
2020-07-06
Active, closed
Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
NCT04199689Papillomavirus Infections
DrugNonavalent HPV vaccine
Merck Sharp & Dohme LLC
Phase 3
6,033
Frankfurt am Main, Berlin, Hamburg
2020-02-27
Active, closed
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
NCT04195750Carcinoma, Renal Cell
DrugsBelzutifan·Everolimus
Merck Sharp & Dohme LLC
Phase 3
755
Tübingen, Düsseldorf, Essen, Dresden, Magdeburg, Jena, Berlin, Hamburg
2020-02-27
Active, closed
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
NCT03407144Hodgkin Lymphoma
DrugsPrednisone/Prednisolone·Vinblastine·Bleomycin·Dacarbazine
Merck Sharp & Dohme LLC
Phase 2
340
Munich, Giessen, Essen, Münster, Berlin
2018-04-09
Rows per page Showing 1–40 of 40
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 September 2026. https://priyalifescience.com/clinical-trials-germany/city/berlin

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 40 of those studies with a site in Berlin that also match the filters currently applied.

How many clinical trials are recruiting in Berlin?

21 of the 40 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 0 have not yet opened recruitment, 19 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Berlin), 40 studies
PhaseStudiesRecruitingShare
Phase 3221055%
Phase 213732.5%
Phase 1/24310%
Phase 2/3112.5%

Most active sponsors

Lead sponsors with the most studies (Berlin)
Lead sponsorStudiesRecruiting
Merck Sharp & Dohme LLC4021
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.